Ipsen back of the pack on the SRD
While remaining for purchase on Ipsen, Gilbert Dupont decided Monday to withdraw the value of its favorite value list 'Midcap', arguing that "the handsome fellow course of action for a month (+9.4% ), compared with a performance of CAC Mid & Small190 limited to 0.6%, now leaves a potential stock market growth below 15%.
The withdrawal gave the lead in the wing during the specialist medicines, while trying again to exceed 40 euros. Around 15 hours, the action Ispen yielded 2.05%, to 38.75 euros, and signs the worst performance of the DRS on Monday.
However, the broker said it maintains its price target to 44.80 euros. To recall, the pharmaceutical group released late October sales up 7.8% to 256.4 million euros in the third quarter and raised in the same time its annual targets.The operating margin has been adjusted between 17 and 17.5% against 14% previously.
Gilbert Dupont has also highlighted the potential for marketing of LPG-1 class in the United States. The FDA (U.S. Health Authority) request to effect different actors perform a series of further clinical trials. Clinical trials are currently being published.
